Our data suggest that FGFR2 mutations occur more often in the well and moderately differentiated endometrioid tumors (G1, G2) compared to undifferentiated tumors and possibly identify the “bad actors” in an otherwise better prognosis histological subgroup. This evidence concerns the gene FGFR2 and endometrioid tumor.